Navigating the Wegovy® Shortage: When Will Starter Doses Be Available and What Are Your Options?

Last reviewed: July 8, 2026

Last updated: July 8, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Demand for GLP-1 receptor agonists has outpaced pharmaceutical supply chains, leaving many patients unable to access brand-name Wegovy® starter doses. PlexusDx addresses this gap by delivering pharmaceutical-grade compounded semaglutide from licensed 503A compounding pharmacies, ensuring consistent availability across all 50 states without insurance requirements.

Understanding the Wegovy® Supply Challenge and Timeline

Novo Nordisk has repeatedly announced capacity constraints affecting Wegovy® availability since 2023. While manufacturing improvements have increased overall production, demand from both new and existing patients continues to exceed supply in many regions. Starter dose packs—critical for patients beginning GLP-1 therapy—remain particularly difficult to obtain through traditional retail and specialty pharmacies.

The shortage has created a 4- to 8-week average wait time in multiple states, forcing patients to postpone treatment initiation or abandon their weight management goals. Some healthcare providers report allocating available doses to established patients rather than onboarding new users. This supply uncertainty has prompted millions of patients to explore compounded alternatives that offer immediate access without inventory delays.

What Compounded Semaglutide Is and How It Differs from Brand-Name Wegovy®

Compounded semaglutide is manufactured by licensed 503A compounding pharmacies using the same active pharmaceutical ingredient (semaglutide) found in Wegovy®. The difference lies in production: brand-name Wegovy® is manufactured at scale by a single FDA-regulated facility, while compounded versions are prepared in state-licensed pharmacies under strict quality standards. Both deliver the identical hormone to your GLP-1 receptors, producing equivalent metabolic effects on appetite suppression and blood sugar regulation.

503A compounding pharmacies operate under federal and state oversight, including USP <797> sterility standards for injectable preparations. PlexusDx partners exclusively with licensed 503A facilities—never 503B outsourcing operations—ensuring your medication meets pharmaceutical-grade standards. The compounding approach allows for flexible dosing, faster fulfillment, and consistent availability that brand-name supply chains cannot currently guarantee.

PlexusDx Semaglutide Injection Pricing and Access Without Insurance Barriers

PlexusDx compounded semaglutide injections are $189/mo month-to-month, or from $149/mo on the 6-month plan, a price that remains flat regardless of your dose progression. This pricing model eliminates the uncertainty patients face with tiered dosing structures—your dose may need to go up, but your price won't. PlexusDx serves all 50 states with no insurance requirement, membership fee, or hidden costs, making initiation straightforward for uninsured or underinsured patients.

Medications from PlexusDx are HSA and FSA eligible, allowing patients to use pre-tax healthcare savings accounts to pay for treatment. This tax advantage can reduce your net out-of-pocket cost by 20–35% depending on your bracket. Unlike Wegovy®, which requires insurance pre-authorization and often involves weeks of appeals, PlexusDx patients begin therapy within 3–5 business days of consultation and payment.

Genetic Testing to Optimize Your GLP-1 Response and Treatment Success

The PlexusDx Precision Peptide Genetic Test ($298) analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to semaglutide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

The test evaluates key genetic variants including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313—markers known to influence appetite sensitivity and weight loss trajectory on GLP-1 therapy. Results guide your clinician in personalizing your starting dose, titration speed, and compound selection (semaglutide versus tirzepatide), reducing trial-and-error and accelerating your path to sustainable weight management.

Comparing PlexusDx Semaglutide Options: Injection vs. Oral Formulation

PlexusDx offers both injectable and oral compounded semaglutide to match your preference and lifestyle. Semaglutide injections ($189/mo flat) deliver consistent weekly dosing via subcutaneous self-injection, mirroring the Wegovy® administration schedule. Oral semaglutide ($289/mo) provides a tablet alternative for patients who prefer to avoid injections, though it requires fasting and specific timing protocols to optimize absorption.

Injectable semaglutide produces more predictable pharmacokinetics and is often chosen by patients prioritizing maximum efficacy and dose flexibility. Oral formulations appeal to needle-averse patients but require stricter adherence to administration guidelines. Your PlexusDx clinician will help you select the formulation best suited to your medical history, preferences, and weight loss targets during your initial consultation.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Will Wegovy® starter doses become widely available soon?

Novo Nordisk projects continued supply constraints through late 2024, with full inventory normalization uncertain. Rather than wait, PlexusDx provides pharmaceutical-grade compounded semaglutide available immediately across all 50 states, allowing you to begin treatment without delays.

Is compounded semaglutide as effective as brand-name Wegovy®?

Yes. Compounded semaglutide contains the identical active ingredient and produces equivalent GLP-1 receptor activation, appetite suppression, and weight loss outcomes. The difference is manufacturing location and supply reliability, not clinical efficacy. Both are supported by extensive clinical trial data demonstrating 15–22% body weight reduction over 68 weeks.

How quickly can I start treatment with PlexusDx semaglutide?

Most patients begin therapy within 3–5 business days of completing their online consultation and payment. Your compounded semaglutide is prepared by a licensed 503A pharmacy and ships directly to your home, eliminating pharmacy wait times and insurance delays common with brand-name Wegovy®.

Can I use my HSA or FSA to pay for PlexusDx semaglutide?

Yes. PlexusDx compounded medications are HSA- and FSA-eligible, allowing you to use pre-tax healthcare dollars and reduce your net out-of-pocket cost by up to 35% depending on your tax bracket.

What is the Precision Peptide Genetic Test, and who should take it?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (MC4R (rs17782313)) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Wegovy Doses
• Ro Wegovy
• Mochi Wegovy
• Noom Wegovy

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.